Abbott pursues new inflammatory skin disease in Humira expansion
This article was originally published in Scrip
Executive Summary
Abbott has begun two Phase III trials investigating the safety and efficacy of its fully human anti-TNF monoclonal Humira (adalimumab) in adult patients with moderate to severe hidradenitis suppurativa (HS), a potential new indication for the drug.